PCI allows the 2022-23 DPharm batch to register and obtain licenses after NBEMS indefinitely defers the exit exam scheduled for October 2024. This decision enables graduates to start their careers, and PCI seeks Union health ministry approval to amend the exit exam regulation from three papers to one.